Aisa Medical Secures Over RMB 100 Million in Series B Funding Led by Qiming Venture Partners to Advance Digital Clinical CRO Platform

Recently, Aisha Medical, a digital clinical CRO focused on post-launch services for innovative drugs and medical devices, announced the completion of its Series B financing round, raising over RMB 100 million. The round was led by Qiming Venture Partners, with participation from Daohe Zhiyi and Sikeruixin, while existing shareholder Boxing Capital continued to increase its investment. MaiBo Capital served as the exclusive financial advisor. The proceeds will be primarily used for talent acquisition, market expansion, and further product iteration of its one-stop clinical service platform.

Aisha Medical, established in 2013, is an innovative digital clinical CRO company dedicated to providing post-marketing clinical research, academic marketing, patient management, and related technology R&D services for innovative pharmaceutical and medical device enterprises both domestically and internationally. In recent years, with the booming development of China’s innovative drug and medical device market, the demand for post-marketing clinical research services has been surging. As a digital CRO company deeply rooted in the post-marketing sector, Aisha Medical boasts a technical platform R&D team of nearly 100 members and possesses the most comprehensive and leading digital product matrix in the industry. Meanwhile, by meticulously refining its service system, the company has successfully pioneered an innovative clinical research operation and management model based on digital technologies, significantly enhancing the management efficiency and scope of clinical studies. It has also developed core capabilities to redefine industry service processes, organizational standards, and cost structures. Taking a nationwide, multi-center RCT study in a certain chronic disease field as an example, Aisha Medical, leveraging its innovative technology platform and operational management model, successfully reduced costs by 70%%The project's operational costs have significantly enhanced the value realization of the product post-launch, earning widespread recognition from customers and clinicians.

Currently, Aisha Medical has successfully expanded its disease service portfolio to cover multiple therapeutic areas, including hepatology, oncology, hematology, anesthesiology, endocrinology, rare diseases, nephrology, respiratory medicine, neuroscience, and gastroenterology, and has successfully operated more than 400 research studies. While providing in-depth services to corporate clients, Aisha Medical has, in recent years, undertaken and successfully delivered multiple national-level scientific research projects, such as those under the 11th, 12th, and 13th Five-Year Plans, the largest real-world study on chronic hepatitis B in China, and the largest prospective randomized controlled cohort study on diabetes in China. Notably, during the COVID-19 pandemic, Aisha Medical undertook several COVID-19 research projects led by the Ministry of Science and Technology of China and Peking University First Hospital. By leveraging digital technologies and remote clinical techniques, the company completed the entire spectrum of clinical research activities online, including data collection, monitoring, and statistical analysis, earning widespread acclaim from the Ministry of Science and Technology of China, Peking University First Hospital, and the medical and research staff at Wuhan Leishenshan Hospital.

While serving pharmaceutical companies, research institutions, and clinicians, Aisha Medicine places particular emphasis on the continuous and in-depth accumulation of industry chain resources. Currently, the Aisha Medicine service platform has aggregated thousands of research institutions and hundreds of thousands of hospital- and enterprise-based users, amassing vast data assets, extensive medical knowledge bases, and algorithms related to clinical trials. These digital assets, in turn, feed back into Aisha’s digital platform, driving continuous innovation and in-depth development of its digital clinical platform. In terms of industrial collaboration, Aisha Medicine consistently pursues model innovation and ecosystem empowerment. It jointly established an integrated platform for amyotrophic lateral sclerosis (ALS) drug development and patient management in the rare disease field with Mr. Cai Lei of JD.com, leveraging its own resources and technical operational advantages to support the establishment of an innovative drug development system for ALS. Additionally, it entered into a strategic partnership with the Guangdong Zhong Nanshan Medical Foundation for the “Respiratory Health Screening for 10,000 People” public welfare project, utilizing digital technologies to facilitate efficient scientific research and public welfare project management.

Regarding this round of financing,Tian Yongqian, Founder and CEO of Aisha MedicalHe stated: “We are deeply grateful to Qiming Venture Partners, Daohe Zhiyi, and Cisco Rui Xin for their recognition of the company, and we also extend our sincere appreciation to existing shareholders Boying Capital and Tuojin Capital for their continued support. Dr. Tian Yongqian, who began his career as a physician, has always maintained a profound commitment to clinical research and patient care. Although he has left hospital practice, Dr. Tian still prefers to be addressed as ‘Dr. Tian.’ It is precisely this extensive experience in clinical medicine that enables Aisha Medical to deeply understand the unmet medical needs of clinicians and patients, as well as the R&D requirements of innovative pharmaceutical and medical device companies. Aisha Medical will continue to strengthen connections among all stakeholders, persistently explore more efficient clinical research management models, and consistently accelerate the R&D and clinical validation of innovative drugs and medical devices, thereby serving to address unmet patient needs more effectively and efficiently.”

As a partner at Aisha Medical and the technical lead for the first-generation digital clinical trial management platform at Aisha Medical,Xu Chenchao, Vice President of Clinical Research at Aisha MedicalIt was stated that digitalization of clinical trials is an inevitable global trend, and future clinical trials will necessarily rely on digital enablement and artificial intelligence assistance. In the latter phase of the COVID-19 pandemic, integrating digital technologies into every aspect of clinical trials will not only enhance trial efficiency and reduce the cost of new drug development, but also inevitably bring about a transformation in clinical trial management models.

Qiming Venture PartnersIt was stated that, as an increasing number of innovative drugs and medical devices developed through independent innovation in China enter the market, post-marketing clinical research will play an increasingly important role in generating evidence-based medical data to validate the clinical utility of these products. iSAIL Medical has distinguished itself in the field of post-marketing clinical CRO services by integrating Contract Research Organization (CRO) services with digitalization and artificial intelligence. We will support the continued growth of iSAIL Medical.

Zhou Hao, Partner at Daohe ZhiyiStatement: Daohe remains bullish on the development of post-marketing clinical research and real-world study industries in China. Aisha Medical has become a leading enterprise in China’s post-marketing clinical research sector, thanks to its years of deep engagement and accumulated experience in the industry. Leveraging an innovative clinical research management model based on internet technologies, Aisha has achieved the goals of reducing labor costs and improving clinical trial efficiency. It provides pharmaceutical companies and clinical experts with a comprehensive solution that includes efficient clinical CRO services and AI-driven digital system products. We firmly believe that, through its profound professional capabilities and the all-around empowerment from the Daohe ecosystem and other investors in the pharmaceutical sector, Aisha Medical will emerge as a top-tier innovative clinical CRO enterprise in China.

VCBeat New Partner: Fu DongzheStatement: Life sciences represent humanity’s most pressing need, and the CXO sector serves as the foundation for the development of life sciences. We are delighted to see that Aisha Medical has identified a new breakthrough point within the CXO landscape, carving out a new blue ocean amidst intense competition. We will continue to provide robust support for the growth of Aisha Medical.

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages ten US dollar funds and six RMB funds, with total assets under management exceeding USD 6.2 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in sectors such as TMT and Healthcare. To date, Qiming Venture Partners has invested in more than 430 high-growth innovative enterprises, among which over 170 have been listed on the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange, the Taipei Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange.

With exits via stock exchange listings and mergers, more than 40 companies have become industry-recognized unicorns and super unicorns.

Shanghai Dahe Zhiyi Private Equity Fund Management Co., Ltd. was established in 2021 as a specialized healthcare investment arm under Shanghai Dahe Long-term Investment Management Co., Ltd. The first fund managed by Dahe Zhiyi primarily invests in innovative drugs and high-end medical devices, with a strategic focus on high-quality enterprises that align with three key development pathways and trends in the medical industry: innovation, integration, and internationalization. Shanghai Dahe Long-term Investment Management Co., Ltd. is a long-term investment management firm providing asset allocation products and services to society, and it is the first institution in Shanghai qualified as a private equity asset allocation fund manager. Leveraging Dahe’s asset allocation framework and its full-lifecycle capital ecosystem through the Dahe Sci-Tech Innovation Service System, Dahe Zhiyi deeply cultivates medical subsectors with the greatest industrial and investment value, thereby building a robust healthcare investment ecosystem.

Sicorui Xin is a large, professional equity investment fund management institution approved by the government, and it is also one of the most influential professional management institutions for venture capital funds in China. It focuses on information technology, new energy, advanced manufacturing, biopharmaceuticals, and other high-growth industries. It has invested in many high-tech listed companies such as Huibopu, Netpower, Baozhi Online, Jiesai Technology, Saiwei Intelligence, Xinyuan Technology, Tianyima, Ruiwei Intelligence, and Lingdong Microelectronics, achieving remarkable investment performance.

MedBio Capital is a boutique investment bank specializing in the life sciences and healthcare sectors, dedicated to serving as a capital and strategic partner to leading scientists and entrepreneurs. Its core team has extensive experience in the medical industry, covering key stages from R&D and clinical development to market commercialization, and possesses multidisciplinary expertise in investment, investment banking, and consulting. Team members have collectively facilitated over RMB 10 billion in financing and have provided services to more than ten top-tier publicly listed healthcare companies.